Clinical Trial Update: A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating patient perception and quality of life with olopatadine 0.2% for allergic conjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Pataday 0.2% (olopatadine) (olopatadine)

Snippet

Sponsor: Alcon Research | Conditions: Allergic Conjunctivitis | Phase 4 | Status: COMPLETED